Enhancing Hepatitis C Care for People Experiencing Homelessness: A Patient-Centered Primary Care Approach

Marguerite Beiser, NP
Boston Health Care for the Homeless Program
5/29/14
Outline

• The Problem
  ▫ HCV in the US is epidemic
  ▫ HCV disproportionately impacts marginalized populations

• The Opportunity
  ▫ Rapidly evolving science affords cure at high rate

• The Response
  ▫ Empower Health Care for the Homeless Programs to utilize opportunity
The Problem

- Hepatitis C (HCV)- High prevalence, communicable chronic illness
  - 1.0% US prevalence NHANES Survey (Denniston et al, 2014)
    - ~2.2-3.2 million Americans
    - **NHANES underreports persons who are incarcerated and homeless
  - 23% at BHCHP (Bharel et al, 2013)
  - 22-52% across Health Care for the Homeless Programs in the US (Strehlow et al, 2012)
  - 12-35% in incarcerated populations (Weinbaum et al, 2003)
Chronic HCV Infection

Fibrosis
- Chronic HCV infection can lead to the development of fibrous scar tissue within the liver

Cirrhosis
- Over time, fibrosis can progress, causing severe scarring of the liver, restricted blood flow, impaired liver function, and eventually liver failure

Hepatocellular Carcinoma (with cirrhosis)
- Cancer of the liver can develop after years of chronic HCV infection

Chronic liver disease includes fibrosis, cirrhosis, and hepatic decompensation; HCC=hepatocellular carcinoma.


Utilized with permission from Cami Graham, MD BIDMC
Projected Numbers of Decompensated Cirrhosis and Cases of HCC to Rise Through 2020

- Decompensated cirrhosis became more common after 1995 and is presently estimated at 11.7% of cirrhosis cases; the number of cases is expected to continue to increase through ~2020-2030
- HCC rose steeply after 1990. Based on the model, the incidence of HCV-related HCC is expected to peak in 2019 at almost 14,000 cases per year if the risk in HCV-infected persons with fibrosis remains the same

HCC=hepatocellular cancer; HCV=hepatitis C virus.

Utilized with permission from Cami Graham, MD, BIDMC


Mortality among HCV cases in Massachusetts

Timing of mortality among known HCV cases in Massachusetts, 1992-2009

Median interval: 3 years
Median age: 53 years

N=8,499

76,122 HCV diagnoses were reported to the MDPH between 1992 and 2009, 8,499 of these reported HCV cases died and are represented in the figure. Data as of 1/11/2011.
Historic HCV care limitations

- Barriers to HCV care:
  - Access
  - Attitude
  - Competing Priorities
  - Expertise

- 3% of BHCHP patients with hepatitis C ever started on treatment (Ard and Bharel, unpublished data)

Cascade of care describes scope of missed opportunities (Holmberg et al, 2013)
The Opportunity

- The advent of very tolerable, highly efficacious direct-acting antiviral (DAA) medications to treat HCV enables broad application of curative treatment to previously hard to reach/hard to treat groups
Rapid Evolution of HCV Regimens: Easier to Tolerate, Higher SVR, All Oral for Most Patients by Late 2014

<table>
<thead>
<tr>
<th>Year</th>
<th>Genotype 1</th>
<th>Genotype 2</th>
<th>Genotype 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>Telaprevir + P/R</td>
<td>P/R</td>
<td>P/R = Pegylated interferon alfa plus ribavirin</td>
</tr>
<tr>
<td>2014</td>
<td>Sofosbuvir* + RBV x12 wks</td>
<td>Sofosbuvir* + RBV x 24 wks</td>
<td>Sofosbuvir+ Simeprevir+/-R x12 wks</td>
</tr>
<tr>
<td>2015</td>
<td>Sofosbuvir + Ledipasvir +/- RBV x 8-12 wks</td>
<td>ABT-450/RTV + ABT-267 + ABT-333 + RBV x 12 wks</td>
<td>Daclatasvir + Asunaprevir (?geno1b)</td>
</tr>
</tbody>
</table>

*Approval for SMV 11/26/13 and SOF 12/6/13

Derived from National AIDS Treatment Advocacy Project; http://www.natap.org/2012/HCV/082912_01.htm
SVR-12 in Genotype 1 Patients Treated with Sofosbuvir+Ledipasvir (FDC)

Utilized with permission from Cami Graham, MD, BIDMC

Gilead Phase 3 Program:
- Genotypes 1a and 1b combined for all studies
- ION-1 with 15.7% cirrhosis
- ION-2 with 20% cirrhosis
- Filed with FDA 2/10/14 so we anticipate approval in mid-Oct 2014

Gilead press release 12/18/13
SVR (Cure) Associated with Decreased All-Cause Mortality

530 patients with advanced fibrosis, treated with interferon-based therapy, and followed for 8.4 (IQR 6.4-1.4) years
Treatment in the community

- Established models of HCV treatment in community settings
  - **Project ECHO** (Arora et al, 2012)
  - Treatment linked to opiate substitution therapy
  - Homegrown efforts
    - MGH Charlestown, BMC GIM, GLFHC
  - At BHCHP
    - HRSA SPNS Ryan White HCV Treatment Expansion Initiative

As treatments become less nuanced and less toxic, PCMH and HCH programs offer excellent frames to enable integrated services for HCV treatment
HCV at BHCHP

- Implementation of HCV treatment required assessment of:
  - current patient needs
    - Anecdotal experience during SPNS suggested poor uptake of HCV treatment
    - Fears about side effects
    - Lack of perceived need for treatment
    - Competing priorities
  - current standards of HCV care in primary care
  - capacity to treat patients with limited resource allocation
HCV Needs Assessment Survey

• Objectives:
  ▫ Conduct an survey of BHCHP patients with HCV to elucidate the knowledge level and unique concerns of homeless persons around HCV treatment
  ▫ Utilize survey data to establish a tailored, comprehensive HCV treatment program that promotes cure in people experiencing homelessness, despite barriers
HCV Needs Assessment Survey

• 32-item self-administered questionnaire
• English and Spanish
• Administered from October 2013-January 2014
  ▫ Jean Yawkey Place – PCMH-recognized clinic
  ▫ Barbara McInnis House – medical respite center
  ▫ Pine St. Inn – shelter clinic
  ▫ Saint Francis House – shelter clinic
What concerns you most about living with hepatitis C?

"My concerns about having hep C is that if I don't protect myself either I can die of it and I can infect others."
- study respondent

“I honestly don’t think about it enough.”
- study respondent

“Not being able to have a serious relationship with someone who is not infected and may be biased.”
- study respondent

“Dieing of liver cancer.”
study respondent
## HCV Needs Assessment

### Table 1. Demographic Characteristics N=240

<table>
<thead>
<tr>
<th>General Demographics</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>177</td>
<td>80.1</td>
</tr>
<tr>
<td>Female</td>
<td>40</td>
<td>18.1</td>
</tr>
<tr>
<td><strong>Ethnicity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>47</td>
<td>21.3</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>118</td>
<td>49</td>
</tr>
<tr>
<td>Black or African American</td>
<td>59</td>
<td>25</td>
</tr>
<tr>
<td>American Indian or Alaska Native</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>More than one race/mixed race</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>Other</td>
<td>32</td>
<td>13</td>
</tr>
<tr>
<td>Prefer Not to answer</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td><strong>Housing Status</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shelter</td>
<td>147</td>
<td>66</td>
</tr>
<tr>
<td>Street</td>
<td>43</td>
<td>19</td>
</tr>
<tr>
<td>Housed</td>
<td>57</td>
<td>26</td>
</tr>
<tr>
<td>Other</td>
<td>34</td>
<td>15</td>
</tr>
<tr>
<td><strong>Self-reported Substance Abuse</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of any drugs in the past month</td>
<td>91</td>
<td>41.2</td>
</tr>
<tr>
<td>Use of Injected Drugs in the past month</td>
<td>43</td>
<td>19.6</td>
</tr>
<tr>
<td>Excessive alcohol use in the past week</td>
<td>39</td>
<td>17.7</td>
</tr>
<tr>
<td>Attendance of methadone or suboxone clinic</td>
<td>71</td>
<td>32.6</td>
</tr>
</tbody>
</table>

### Figure 1. Duration of known HCV infection N=225

- A year or less: 12
- 1-5 years: 19
- 5-10 years: 26
- 10-20 years: 29
- Greater than 20 years: 14
HCV Knowledge Level

Figure 2. Hepatitis C knowledge level of survey respondents based on a seven item exercise  N=240

Examples of knowledge questions:

- Can hepatitis C be spread through sharing needles or works?
- Is there a hepatitis C vaccine?
- Can hepatitis C cause cirrhosis?
- Does having HIV infection increase the risk of liver damage if you have hepatitis C?
- Is there a treatment that can cure hepatitis C infection?
## Treatment factors and preferences

### Table 2. Respondents’ motivating factors for HCV treatment  N=240

<table>
<thead>
<tr>
<th>Motivating factors (total) N=240</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taking care of your health *</td>
<td>146</td>
<td>60.8</td>
</tr>
<tr>
<td>Your provider says you should get treated *</td>
<td>107</td>
<td>44.6</td>
</tr>
<tr>
<td>You are clean</td>
<td>94</td>
<td>39.2</td>
</tr>
<tr>
<td>Treatment that doesn’t make you sick</td>
<td>91</td>
<td>37.9</td>
</tr>
<tr>
<td>Feeling sick from hepatitis C</td>
<td>84</td>
<td>35</td>
</tr>
<tr>
<td>Housing is stable</td>
<td>63</td>
<td>26.3</td>
</tr>
<tr>
<td>Loved ones say you should get treated</td>
<td>53</td>
<td>22.1</td>
</tr>
<tr>
<td>Other</td>
<td>36</td>
<td>15</td>
</tr>
</tbody>
</table>

* statistically significant with a p value of <= 0.05

### Table 3. Respondents’ preferred location for HCV treatment N=240

<table>
<thead>
<tr>
<th>Where would you feel most comfortable receiving treatment for hepatitis c?</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Care office</td>
<td>127</td>
<td>53%</td>
</tr>
<tr>
<td>Liver doctor’s office</td>
<td>88</td>
<td>37%</td>
</tr>
<tr>
<td>Suboxone/methadone clinic</td>
<td>17</td>
<td>7%</td>
</tr>
<tr>
<td>Other healthcare setting</td>
<td>11</td>
<td>5%</td>
</tr>
<tr>
<td>Anywhere/Not sure/Other</td>
<td>22</td>
<td>10%</td>
</tr>
</tbody>
</table>

* statistically significant with a p value of <= 0.05
Treatment factors

86% report **interest** in HCV treatment

74% are **confident** they could complete HCV treatment

<table>
<thead>
<tr>
<th>Wishes for additional support services to assist with hepatitis C treatment</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barbara McInnis House/respite center</td>
<td>143</td>
<td>60</td>
</tr>
<tr>
<td>Help with medication</td>
<td>86</td>
<td>36</td>
</tr>
<tr>
<td>Behavioral Health (psychiatry and counseling)</td>
<td>82</td>
<td>34</td>
</tr>
<tr>
<td>Case management</td>
<td>81</td>
<td>34</td>
</tr>
<tr>
<td>Help with housing</td>
<td>79</td>
<td>33</td>
</tr>
<tr>
<td>Support groups</td>
<td>72</td>
<td>30</td>
</tr>
<tr>
<td>Substance abuse treatment</td>
<td>65</td>
<td>27</td>
</tr>
<tr>
<td>Nutritional/meal support</td>
<td>58</td>
<td>24</td>
</tr>
<tr>
<td>Other</td>
<td>31</td>
<td>13</td>
</tr>
</tbody>
</table>
HCV Needs Assessment Survey

Conclusions

• First of its kind HCV needs-assessment in a homeless health care setting
  ▫ Homeless persons have high levels of knowledge about HCV
  ▫ The majority of homeless persons desire HCV treatment and are confident they can complete treatment
  ▫ Primary care teams fulfill an essential role
    • Educating along continuum of prevention → cure
    • Motivating individuals to receive treatment
    • Preferred location for treatment
Next Steps

• Empower primary care teams
  ▫ Implement health center-specific guidelines for screening and routine care for this special population

• Increase capacity to cure
  ▫ Provide person-centered HCV treatment by expert staff on site

• Share successful models for HCV treatment in this special population with local and national partners
Primary Care HCV care guidelines

- Developed based on review of current guidance
- Tailored to high prevalence, limited resource setting

Screening

Evaluation for/monitoring of chronic HCV

Assessment of liver fibrosis

Treatment evaluation
Screening

• All patients at BHCHP should receive **one-time screening for hepatitis C by hepatitis C antibody testing** regardless of risk factors.

• Follow-up annual antibody screening should be conducted for patients who are at high risk to acquire HCV.

• Patients with a previous exposure to HCV (HCV antibody positivity) but an undetectable HCV viral load due to spontaneous viral clearance or treatment, should undergo annual screening with HCV viral load if they have ongoing risk factors as HCV antibody-positivity is not protective against reinfection.
# Evaluation of chronic HCV

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Q6mo <strong>cirrhosis only</strong></th>
<th>Annually</th>
<th>only w/symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV viral load (RNA)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCV genotype</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBC/diff</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>PT/INR</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>BMP/LFTs</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Abd U/S</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Cryoglobulins</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Fib-4 index</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>HIV Antibody</td>
<td>X</td>
<td></td>
<td>X</td>
<td>if risk factors</td>
</tr>
<tr>
<td>HAV screening</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBV screening</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endoscopy</td>
<td></td>
<td></td>
<td></td>
<td>At time of cirrhosis diagnosis- FU based on results</td>
</tr>
</tbody>
</table>

**Preventive Screening**
- **Hepatitis A Screen**
  - HAV Ab (-) → Vaccinate
  - HAV Ab (+) → Immune
- **Hepatitis B Screen**
  - HBsAb (-) & HBsAg (-) → Vaccinate
  - HBsAb (+) & HBsAg (-) → Immune
  - HBsAb (-) & HBsAg (+) → Co-infection w/HBV
- **HIV Screen**
  - HIV Ab (+) → Co-infection w/HIV

**Preventive Immunizations**
- Influenza vaccination
- Pneumococcal vaccination

**Alcohol Use** → Brief Intervention/Referral if indicated
# Fibrosis Assessment

## Selected Noninvasive Systems to Assess Liver Fibrosis in Chronic Hepatitis C

<table>
<thead>
<tr>
<th>Marker</th>
<th>Description</th>
<th>Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST to platelet</td>
<td>$(\text{AST level/ULN x 100})/\text{platelet count}$</td>
<td>Threshold of 0.7 has a sensitivity of 77% and specificity of 72% for significant fibrosis (Metavir stage 3 or 4)$^{13}$</td>
</tr>
<tr>
<td>ratio index (APRI)</td>
<td></td>
<td>Index of &gt; 3.25 has PPV of 82% with a specificity of 98% for significant fibrosis (Metavir stage 3 or 4)$^{14}$</td>
</tr>
<tr>
<td>FIB-4 index</td>
<td>$(\text{Age (yrs)} \times \text{AST (IU/mL)})/\left(\text{platelets (x 1000) x ALT (IU/mL)}\right)^{1/2}$</td>
<td>Sensitivity of 75% and specificity of 85% to detect Metavir stage 2 or greater$^{15}$</td>
</tr>
<tr>
<td>FibroTest</td>
<td>Calculation including age, haptoglobin, alpha-2-macroglobulin, apolipoprotein A1, GGT, and total bilirubin</td>
<td>Threshold for diagnosis of cirrhosis 12.5 KPa with sensitivity of 87% and specificity of 91%$^{16,17}$</td>
</tr>
<tr>
<td>FibroScan</td>
<td>Ultrasound device that uses transient elastography to assesses liver shear wave velocity (meters/second) that is converted to equivalent liver stiffness (kilopascals) at 50 Hz, which correlates with hepatic fibrosis stage</td>
<td></td>
</tr>
</tbody>
</table>

In the interest of applying an accurate, easily administered, cost-effective measure that enables BHCHP to identify the highest risk patients for morbidity and mortality to the large population of patients with HCV at BHCHP, the Fib-4 index is chosen as the preferred fibrosis staging instrument.

Fib-4 index $= (\text{age (yrs)} \times \text{AST (IU/mL)})/\left(\text{platelets (x1000) x ALT (IU/mL)}\right)^{1/2}$
Assessment of liver fibrosis and cirrhosis management at BHCHP

**Liver Fibrosis Assessment**
- Goal - to predict advanced fibrosis and cirrhosis
- Liver function tests, platelets and INR are **late** predictors of cirrhosis and are not useful in early fibrosis

Fib-4 index - a validated calculation to predict fibrosis using age, ALT, AST and platelet levels. Recommended annually.
- 
  - <1.45 = highly suggestive of minimal fibrosis (F0-F1)
  - >3.25 = highly suggestive of advanced fibrosis (F3-F4)
  - 1.46-3.24 = indeterminate level of fibrosis

**Reference: Metavir scale of fibrosis**
- F0 = no fibrosis.
- F1 = portal fibrosis w/o septa.
- F2 = few septa.
- F3 = numerous septa w/o cirrhosis
- F4 = cirrhosis.

**Cirrhosis Management** - Consider Fib-4 scores >3.25 highly suggestive of cirrhosis and implement cirrhosis monitoring by:
- Screen for HCC with abdominal u/s q6 months
  - AFP testing lacks adequate sensitivity/specificity to be an effective surveillance tool and is no longer recommended
- Screen for esophageal varices with endoscopy
- Recommend referral to GI for management of complications r/t decompensated cirrhosis
  - Ascites
  - esophageal varices
  - portal hypertension
HCV Education in Primary Care

Guidance for Patients

HCV Infection is a blood-borne virus that affects the liver and, for some people, can cause scarring, cirrhosis and liver cancer over the course of many years.

Risk factors for disease progression include alcohol consumption, HIV coinfection, concomitant liver disease, obesity, age, genetic factors

Patient Education

- Avoid sharing toothbrushes and dental or shaving equipment and cover any cut or sore in order to prevent contact of their blood with others.
- Stop using illicit drugs. Get treatment for substance abuse. **Those who continue to inject drugs should avoid reusing or sharing syringes, needles, water, cotton or other paraphernalia**; use only sterile syringes from a reliable source (e.g., pharmacy, needle exchange); use a new sterile syringe to prepare and inject drugs; use sterile water to prepare drugs – otherwise use clean water from a reliable source (e.g. tap); clean the injection site with a new alcohol swab; and dispose of syringes and needles after one use in a safe, puncture-proof container.
- Do not donate blood, body organs, other tissue, or semen.
- If the patient has high risk sexual behavior (including multiple sex partners, anal sex or rough sex/fisting), recommend barrier precautions (e.g., latex condoms or gloves) and “safer” sex. Otherwise, the risk of sexual transmission of HCV is low, and the infection itself is not a reason to change sexual practices (i.e., those in long-term relationships need not start using barrier precautions).
- To protect the liver from further harm: do not drink alcohol; do not start any new medicines, including over-the-counter and herbal medicines, without checking with their provider.
BHCHP HCV Consult Service

- Started in 1/14 by NP, MD and RN with some experience in HCV treatment and >50 hours of CME
- Key elements
  - Specialty back-up
    - ID/GI/pharmacy
  - Administrative buy-in
  - Insurance expertise
  - Adherence support
    - Med storage
    - Frequent and flexible patient check-ins

50 patients seen since 1/27/14
7 patients treated
5/5 in first group achieved RVR
HCV Treatment in primary care of persons experiencing homelessness

**Treatment** - Who is appropriate for treatment?

- Urgency of treatment should be based on likelihood of *advanced fibrosis* (F3-F4).
- If a patient is highly motivated, and understands there are future treatment options but wants treatment now, they should be evaluated for treatment candidacy.
- Refer to BHCHP HCV Consult Service for education, treatment evaluation and initiation.

What about cost?

What about reinfection?

Other concerns?
Resources

• Treatment Guidelines
  ▫ AASLD and IDSA guidelines www.hcvguidelines.org
  ▫ Hepatitis C Online University of Washington http://www.hepatitisc.uw.edu/browse/all/lectures
  ▫ Clinical Care Options Hepatitis www.clinicaloptions.com

• Hepatitis C news and conference proceedings
  ▫ www.natap.org
  ▫ www.hivandhepatitis.com

• Advocacy and patient education
  ▫ HepMag www.hepmag.com
  ▫ Hcvadvocate.org
  ▫ National Viral Hepatitis Roundtable www.nvhr.org
Acknowledgements

- The patients and staff at Boston Health Care for the Homeless Program
- Kraft Center for Community Health
- HRSA SPNS Hepatitis C Treatment Expansion Initiative
- Jessie Gaeta, MD; Casey Leon, MPH; Claire Carlo, MD; Carole Hohl, PA; Sandy Sheble-Hall, RN; Ioana Bica, MD; David Nunes, MD; Arthur Kim, MD; Cami Graham, MD; Georgia Thomas
- MA Viral Hepatitis Coalition
- MA Department of Public Health Division of Viral Hepatitis